You have 9 free searches left this month | for more free features.

Relapsed/Refractory Multiple Myeloma

Showing 26 - 50 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Relapsed/Refractory Multiple Myeloma Trial in Louisville, Boston (agenT-797)

Active, not recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Louisville, Kentucky
  • +2 more
Oct 21, 2022

Multiple Myeloma Trial in Paris (Idecabtagene vicleucel, Not treated)

Active, not recruiting
  • Multiple Myeloma
  • Idecabtagene vicleucel
  • Not treated
  • Paris, France
    DESCAR-T Registry
Nov 27, 2023

Relapsed/Refractory Multiple Myeloma Trial in Xi'an (LUCAR-B68 cells product)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • LUCAR-B68 cells product
  • Xi'an, Shaanxi, China
    Second Affiliated Hospital of Xi'an Jiaotong University
Aug 10, 2022

Multiple Myeloma Trial in New York (Iberdomide, Elotuzumab, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • New York, New York
    Icahn School of Medicine
Jan 20, 2023

Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Rapid Infusion Isatuximab)

Withdrawn
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Rapid Infusion Isatuximab
  • (no location specified)
Jul 3, 2022

Multiple Myeloma Trial in Houston (Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A))

Not yet recruiting
  • Multiple Myeloma
  • Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
  • Houston, Texas
    The University of Texas MD Anderson Cancer Center
Jan 13, 2023

Multiple Myeloma, Relapse Multiple Myeloma Trial in Bethesda, Madison (Descartes-25)

Recruiting
  • Multiple Myeloma
  • Relapse Multiple Myeloma
  • Shreveport, Louisiana
  • +3 more
Nov 4, 2022

Medicine Called Elranatamab in People With Relapsed Refractory

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Jun 30, 2023

Relapsed/Refractory Multiple Myeloma Trial (Isatuximab, Carfilzomib, Dexamethasone)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • (no location specified)
Feb 3, 2023

Patients With Relapsed/Refractory Multiple Myeloma

Not yet recruiting
  • Relapsed and Refractory Multiple Myeloma (RRMM)
  • Non-Interventional
  • (no location specified)
Dec 21, 2022

Multiple Myeloma Trial in Athens (Cevostamab, XmAb24306, Tocilizumab)

Recruiting
  • Multiple Myeloma
  • Athens, Greece
  • +1 more
Jan 2, 2023

Myeloma Multiple Trial (Off Drug Surveillance)

Not yet recruiting
  • Myeloma Multiple
  • Off Drug Surveillance
  • (no location specified)
Jun 27, 2023

Multiple Myeloma Trial in New York (drug, biological, procedure)

Active, not recruiting
  • Multiple Myeloma
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 3, 2023

Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory DLBCL Trial in United States (EZM0414)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  • Chevy Chase, Maryland
  • +10 more
Jan 12, 2023

Multiple Myeloma Trial in Hackensack (Bortezomib)

Terminated
  • Multiple Myeloma
  • Hackensack, New Jersey
    The Cancer Center at Hackensack University Medical Center
Jun 24, 2022

Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Elotuzumab, Selinexor, and Dexamethasone (ESd))

Withdrawn
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Elotuzumab, Selinexor, and Dexamethasone (ESd)
  • (no location specified)
Apr 27, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (Actinium Ac 225-DOTA-Daratumumab, Daratumumab,

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Actinium Ac 225-DOTA-Daratumumab
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

Multiple Myeloma Trial in Shanghai (GC012F injection)

Recruiting
  • Multiple Myeloma
  • GC012F injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Jul 23, 2022

Multiple Myeloma Trial in Nashville (Cevostamab, Tocilizumab)

Recruiting
  • Multiple Myeloma
  • Nashville, Tennessee
    Tennessee Onc., PLLC - SCRI
Sep 8, 2022

Multiple Myeloma Trial in Wuhan (Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells)

Recruiting
  • Multiple Myeloma
  • Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 11, 2023

Multiple Myeloma Trial (Elranatamab (PF-06863135))

Temporarily not available
  • Multiple Myeloma
  • Elranatamab (PF-06863135)
  • (no location specified)
Jul 15, 2022

Multiple Myeloma, Immune System Diseases Trial in Chapel Hill (CAR138 T Cells)

Recruiting
  • Multiple Myeloma
  • Immune System Diseases
  • CAR138 T Cells
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jan 10, 2023

Multiple Myeloma, Primary Plasma Cell Leukemia Trial in Shanghai (Experimental: CAR-T cells Infusion)

Not yet recruiting
  • Multiple Myeloma
  • Primary Plasma Cell Leukemia
  • Experimental: CAR-T cells Infusion
  • Shanghai, China
    Shanghai Changzheng Hospital
Apr 20, 2023

Multiple Myeloma Trial in Boston, Columbus (drug, biological, other)

Terminated
  • Multiple Myeloma
  • Boston, Massachusetts
  • +1 more
Nov 14, 2022

Relapsed/Refractory Multiple Myeloma Trial in United States (Belantamab mafodotin)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Belantamab mafodotin
  • Clayton, North Carolina
  • +4 more
May 16, 2023